Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 8/20 | 0.38 |
| ▸ | ACHE | P22303 | 8/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL29227332 | 0.85 | KMT2A (0.42) | KMT2AKDM4EATMMEN1CYP2A6 | |
| SCHEMBL17193116 | 0.75 | TERT (0.44) | KMT2AATMMEN1CYP2A6TDP1 | |
| Bromide SCHEMBL5255425 | 0.74 | KMT2A (0.71) | KMT2AKDM4EATMMEN1SMN1; SMN2 | |
| SCHEMBL2796407 | 0.73 | ATM (0.50) | KMT2AKDM4EATMMEN1CYP2A6 | |
| SCHEMBL25803712 | 0.71 | CYP2A6 (0.39) | KMT2AKDM4EATMMEN1CYP2A6 | |
| SCHEMBL9935936 | 0.67 | ACHE (0.68) | BCHEACHE | |
| SCHEMBL13043235 | 0.67 | KDM4E (0.56) | KDM4ERAB9ASMN1; SMN2NPC1 | |
| SCHEMBL16470252 | 0.65 | MEN1 (0.42) | KMT2AKDM4EATMMEN1CYP2A6 | |
| SCHEMBL25334051 | 0.65 | ACHE (0.67) | KMT2AKDM4EMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL17187221 | 0.64 | CYP2A6 (0.50) | KMT2AKDM4EATMMEN1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546609-B2 | Ionic liquid containing allylsulfonate anion | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| EP-2474527-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | Wako Pure Chemical Industries, Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | ATXN2L, ARL1, INPPL1 | KMT2A 4633/4885KDM4E 4681/4885ATM 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.